Improved biological and transcriptional activity of monopegylated interferon-α-2a isomers

Pharmacogenomics Journal

Volumn 3, Issue 6, 2003, Pages 312-319

  Foser, S ^a   Weyer, K ^a   Huber, W ^a   Certa, Ulrich ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Interferon activity; PEG interferon; Pegylation; Receptor signaling; Transcription

Indexed keywords

DNA; MACROGOL; OLIGONUCLEOTIDE; PEGINTERFERON ALPHA2A;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; DRUG FORMULATION; DRUG PURIFICATION; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; ISOMER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIVIRAL AGENTS; CATTLE; CELL LINE; DOGS; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; STEREOISOMERISM; TRANSCRIPTION, GENETIC;

EID: 0347287025     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500204     Document Type: Article

References (25)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. J Interferon Res 1987; 7: 429-438.
2. Allen G, Diaz MO. Nomenclature of the human interferon proteins. J Interferon Cytokine Res 1996; 16: 181-184.
3. Spiegel RJ. Alpha interferons: a clinical overview. Urology 1989; 34: 75-79.
4. Baron S, Tyring S, Fleischmann Jr WR, Coppenhaver DH, Niesel DW, Klimpel GR et al. The interferons. Mechanisms of action and clinical applications. J Am Med Assoc 1991; 266: 1375-1383.
5. Zeuzem S, Heathcote J, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Exp Opin Investig Drugs 2001; 10: 2201-2213.
6. Reddy KR, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002; 54: 571-586.
7. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-551.
8. Bailon P, Palleroni A, Schaffer CA, Spence C, Wen-Jian F, Porter JE et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon-2a for the treatment of hepatitis C. Bioconjugate Chem 2001; 12: 195-202.
9. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001; 22: 405-417.
10. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998; 1: 352-356.
11. Perry MC, Jarvis B. Peginterferon-α-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 15: 2263-2288.
12. Lamb MW, Martin EN. Weight-based versus fixed dosing of peginterferon (40 kDa) alfa-2a. Ann Pharmacother 2002; 36: 933-938.
13. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S et al. Isolation, structural characterization and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS®). Protein Express Purification 2003; 30: 78-87.
14. Bailon PS, Palleroni AV European Patent No. 809996, 1997.
15. Certa U, Seiler M, Padovan E, Spagnoli GC. High density oligonucleotide array analysis of interferon-alpha2a sensitivity and transcriptional response in melanoma cells. Br J Cancer 2001; 85: 107-114.
16. Uzé G, Lutfalla G, Mogensen KE. α and β interferons and their receptor and their friends and relations. J Interferon Res 1995; 15: 3-26.
17. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 1995; 270: 21606-21611.
18. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 1994; 77: 391-400.
19. Kim SH, Cohen B, Novick D, Rubinstein M. Mammalian type1 interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene 1997; 196: 279-286.
20. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999; 27: 1583-1592.
21. Hardy MP, Owczarek CM, Trajanovka S, Liu X, Kola I, Hertzog PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001; 97: 473-482.
22. Piehler J, Roisman LC, Schreiber G. New structural and functional aspect of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem 2001; 51: 40425-40433.
23. Chang C-CJ, Chen TT, Cox BW, Dawes GN, Stemmer WPC, Punnonen J et al. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999; 17: 793-797.
24. Cohen B, Novick D, Barak S, Rubinstein M. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol 1995; 15: 4208-4214.
25. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol 1997; 274: 661-675.